Summary
53 / 100 · Bulios Score
What speaks for it
- Out of every 100 USD of revenue, 49 USD is left as net profit.
- It holds more cash than debt: $24.0M against $15.7M.
What to watch
- The share price is above the Bulios Fair Price.
- It reports a profit, yet spends more cash than it brings in.
- Revenue growth is slowing: 8.1% a year over the last 3 years against 15% over 5 years.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 37.4 USD for 1 USD of yearly profit.
Valuation in detailIs it growing?
SlowlyRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 15% a year over 5 years. Over the last 3 years it grew by 8.1% a year.
Growth in detailDoes it make money?
ReasonablyWhere 100 USD of revenue goes
- Cost of sales 36 USD
- Research and development 8.2 USD
- Sales and administration 49 USD
- Taxes and other -42 USD
- Net profit 49 USD
Net profit, industry median (Medical - Instruments & Supplies) 8.1 USD
Out of every 100 USD of revenue, 49 USD is left as net profit.
Profitability in detailIs it financially healthy?
YesOver the last 12 months it spent more cash than it brought in. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 12
- Hold 6
- Sell 0
Today's price within the analysts' price targets
The average target of $31 is 20% below today's price. 67% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2024By product
- Product 92%
- Rental Revenue 7.4%
- Service 0.2%
By region
The company reports no revenue by region.
Product brings in 92% of revenue.
Segments in detail